metadata toggle
Clinical particulars
Target species
Dogs.
Indications for use, specifying the target species
For the treatment of flea and tick infestations in dogs.
This veterinary medicinal product provides immediate and persistent killing activity for 1 month for fleas (Ctenocephalides felis and C. canis) and ticks (Rhipicephalus sanguineus, Ixodes ricinus, I. hexagonus and Dermacentor reticulatus).
Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.
The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
For the treatment of demodicosis (caused by Demodex canis)
Contraindications
Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Special warnings for each target species
Parasites need to start feeding on the host to become exposed to lotilaner; therefore the risk of the transmission of parasite borne diseases cannot be completely excluded.aused by Demodex canis)
Special precautions for use
Special precautions for use in animals
All safety and efficacy data have been acquired from dogs and puppies 8 weeks of age and older and 1.3 kg of body weight and greater. Use of this veterinary medicinal product in puppies younger than 8 weeks of age or less than 1.3 kg of body weight should be based on a benefit-risk assessment by the responsible veterinarian.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Wash hands after handling the product.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the physician.
iii) Other precautions
Not applicable
Adverse reactions (frequency and seriousness)
Target species: Dogs
Very rare
(<1 animal / 10,000 animals treated, including isolated reports):
Diarrhoea1,2, Vomiting1,2
Anorexia1,2, Lethargy2
Ataxia3, Convulsion3, Tremor3
1 Mild and transient
2 Typically resolve without treatment
3 Transient in most cases
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See also the last section of the package leaflet for the respective contact details.
Use during pregnancy, lactation or lay
Laboratory studies in rats have not produced any evidence of teratogenic effects, or any adverse effect on the reproductive capacity of males and females. The safety of the veterinary medicinal product in breeding, pregnant and lactating dogs has not been established. Use only according to the benefit-risk assessment of the responsible veterinarian.
Interaction with other medicinal products and other forms of interaction
None known. During clinical testing, no interactions between Credelio chewable tablets and routinely used veterinary medicinal products were observed.
Amounts to be administered and administration route
For oral use.
The veterinary medicinal product should be administered in accordance with the following table to ensure a dose of 20 to 43 mg lotilaner/kg bodyweight.
Strength and number of tablets to be administered
Bodyweight of dog (kg)
Credelio 56 mg
Credelio 112 mg
Credelio 225 mg
Credelio 450 mg
Credelio 900 mg
1.3-2.5
1
>2.5-5.5
1
>5.5-11.0
1
>11.0-22.0
1
>22.0-45.0
1
>45
Appropriate combination of tablets
Use an appropriate combination of available strengths to achieve the recommended dose of 20-43 mg/kg.
Credelio is a palatable chewable flavoured tablet. Administer the chewable tablet(s) monthly with or after food.
For the treatment of demodicosis (caused by Demodex canis)
Monthly administration of the product for two consecutive months is efficacious and leads to a marked improvement of clinical signs. Treatment should be continued until two negative skin scrapings are obtained one month apart. Severe cases may require prolonged monthly treatments. As demodicosis is a multi factorial disease, where possible, it is advisable to also treat any underlying disease appropriately.
Overdose (symptoms, emergency procedures, antidotes), if necessary
No adverse reactions were observed following oral administration to puppies aged 8–9 weeks and weighing 1.3–3.6 kg treated with overdoses of up to 5 times the maximum recommended dose (43 mg, 129 mg and 215 mg lotilaner/kg bodyweight) on eight occasions at monthly intervals.
Withdrawal period(s)
Not applicable.